S. Rubin

1.4k total citations · 1 hit paper
20 papers, 960 citations indexed

About

S. Rubin is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, S. Rubin has authored 20 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Hematology and 7 papers in Molecular Biology. Recurrent topics in S. Rubin's work include Multiple Myeloma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (5 papers) and Estrogen and related hormone effects (4 papers). S. Rubin is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Cancer Treatment and Pharmacology (5 papers) and Estrogen and related hormone effects (4 papers). S. Rubin collaborates with scholars based in Canada, United States and Austria. S. Rubin's co-authors include Dongsheng Tu, Kathleen I. Pritchard, Hyman B. Muss, Keren Sturtz, Antonio C. Wolff, Eric P. Winer, Kate Whelan, Clifford A. Hudis, Alison Stopeck and Paul E. Goss and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

S. Rubin

20 papers receiving 923 citations

Hit Papers

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
    2016 411 citations Paul E. Goss, James N. Ingle et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Rubin Canada 10 562 303 269 247 226 20 960
Naseem J. Zojwalla United States 15 404 0.7× 481 1.6× 429 1.6× 275 1.1× 154 0.7× 26 948
Reginald P. Pugh United States 19 581 1.0× 221 0.7× 217 0.8× 269 1.1× 171 0.8× 34 1.1k
Rangaswamy Govindarajan United States 12 430 0.8× 189 0.6× 427 1.6× 130 0.5× 170 0.8× 39 973
James Hackett United States 16 946 1.7× 425 1.4× 297 1.1× 103 0.4× 195 0.9× 30 1.4k
Philippe Montcuquet France 16 581 1.0× 248 0.8× 247 0.9× 332 1.3× 71 0.3× 38 919
W.P. Steward United Kingdom 13 567 1.0× 159 0.5× 244 0.9× 502 2.0× 123 0.5× 31 1.0k
Mary Cianfrocca United States 14 869 1.5× 533 1.8× 232 0.9× 239 1.0× 62 0.3× 31 1.3k
Gian Luigi Cetto Italy 19 666 1.2× 369 1.2× 290 1.1× 183 0.7× 49 0.2× 59 1.1k
A Mangalik United States 10 917 1.6× 422 1.4× 203 0.8× 368 1.5× 162 0.7× 32 1.4k
R. Basser Australia 15 397 0.7× 115 0.4× 199 0.7× 179 0.7× 195 0.9× 31 731

Countries citing papers authored by S. Rubin

Since Specialization
Citations

This map shows the geographic impact of S. Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Rubin more than expected).

Fields of papers citing papers by S. Rubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Rubin. The network helps show where S. Rubin may publish in the future.

Co-authorship network of co-authors of S. Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of S. Rubin. A scholar is included among the top collaborators of S. Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Rubin. S. Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. 375(3). 209–219. 411 indexed citations breakdown →
2.
Goss, Paul E., James N. Ingle, Kathleen I. Pritchard, et al.. (2016). A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. Journal of Clinical Oncology. 34(18_suppl). LBA1–LBA1. 11 indexed citations
3.
4.
Vickers, Michael M., Christos S. Karapetis, Dongsheng Tu, et al.. (2012). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology. 24(4). 953–960. 38 indexed citations
5.
Vickers, Michael M., Christos S. Karapetis, Dongsheng Tu, et al.. (2011). The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.. Journal of Clinical Oncology. 29(15_suppl). 3601–3601. 5 indexed citations
6.
Sehn, Laurie H., David MacDonald, S. Rubin, et al.. (2011). Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 29(25). 3396–3401. 24 indexed citations
7.
Johnston, S., et al.. (2010). 380 A novel skin assessment tool for inflammatory breast cancer (IBC). European Journal of Cancer Supplements. 8(3). 168–168. 1 indexed citations
8.
Sehn, Laurie H., David MacDonald, S. Rubin, et al.. (2009). Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.. Blood. 114(22). 407–407. 4 indexed citations
9.
10.
White, Darrell, Michael J. Kovacs, Andrew R. Belch, et al.. (2007). Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.. Blood. 110(11). 189–189. 3 indexed citations
11.
Shustik, Chaim, Andrew R. Belch, Sue Robinson, et al.. (2006). A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. British Journal of Haematology. 136(2). 203–211. 58 indexed citations
12.
Shustik, Chaim, Andrew R. Belch, Stephen Robinson, et al.. (2004). Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute Of Canada Clinical Trials Group Study: MY.7. Journal of Clinical Oncology. 22(14_suppl). 6510–6510. 17 indexed citations
13.
14.
15.
Rubin, S., et al.. (2000). Primary Lymphoma of the Liver: A Case Report and Review. Canadian Journal of Gastroenterology and Hepatology. 14(11). 955–957. 14 indexed citations
16.
Patterson, Briana C., et al.. (1999). Acute lymphoblastic leukemia with multiple cytogenetic abnormalities secondary to treatment of Ewing’s sarcoma. Leukemia Research. 23(6). 593–596. 7 indexed citations
17.
Bergsagel, Daniel E., Séamus O’Reilly, Kirsten Wilson, et al.. (1998). Randomized trial of interferon-α maintenance in myeloma patients responding to melphalan and prednisone (MY-6). 6. 129–131. 1 indexed citations
18.
Browman, George P., Daniel E. Bergsagel, Séamus O’Reilly, et al.. (1995). Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 13(9). 2354–2360. 76 indexed citations
19.
Lundgren, Rolf, Torsten Sundin, E Lindstedt, et al.. (1987). Cardiovascular Complications of Estrogen Therapy for Nondisseminated Prostatic Carcinoma. A Preliminary Report from a Randomized Multicenter Study. The Journal of Urology. 137(4). 809–809. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naseem J. Zojwalla Breakdown of academic impact, for papers by Reginald P. Pugh Breakdown of academic impact, for papers by Rangaswamy Govindarajan Breakdown of academic impact, for papers by James Hackett Breakdown of academic impact, for papers by Philippe Montcuquet Breakdown of academic impact, for papers by W.P. Steward Breakdown of academic impact, for papers by Mary Cianfrocca Breakdown of academic impact, for papers by Gian Luigi Cetto Breakdown of academic impact, for papers by A Mangalik Breakdown of academic impact, for papers by R. Basser
Rankless by CCL
2026